Diagnostics and prognostication of myelodysplastic syndromes

Gina Zini Tanzi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

12 Citazioni (Scopus)


MDS are a heterogeneous and complex group of clonal hematological neoplasms arising from a hematopoietic stem cell, and characterized by ineffective hematopoiesis, resulting in increased apoptosis in the bone marrow and peripheral cytopenia, which involves one or more lineages. Epigenetic changes are reported as 'founder' mutations in the case of MDS. Its incidence in the general population has been reported as five new MDS diagnoses per 100, 000 people. It affects men more frequently than it does women, and its incidence increases with age. The diagnostic classification, now in use, is the one of the World Health Organization, revised in August 2016. It recognizes six distinct entities in addition to a provisional entity of childhood. In most of the cases, diagnosis is based on the morphologic quantitative and qualitative evaluation of the peripheral blood and bone marrow using basic hematological techniques. Bone marrow biopsy and flow cytometric immunophenotyping also offer support for further diagnostic elucidation, while cytogenetics and molecular genetics are presently fully integrated into prognostication, treatment processes, and decision-making.
Lingua originaleEnglish
pagine (da-a)465-474
Numero di pagine10
RivistaAnnals of Laboratory Medicine
Stato di pubblicazionePubblicato - 2017


  • Biochemistry (medical)
  • Bone Marrow
  • Chromosome Deletion
  • Chromosomes, Human, Pair 7
  • Clinical Biochemistry
  • Diagnosis
  • Epigenesis, Genetic
  • Erythrocytes, Abnormal
  • Incidence
  • Myelodysplastic Syndromes
  • Myelodysplastic syndromes (MDS)
  • Phosphoproteins
  • Prognosis
  • Prognostication
  • RNA Splicing Factors
  • WHO 2016 classification


Entra nei temi di ricerca di 'Diagnostics and prognostication of myelodysplastic syndromes'. Insieme formano una fingerprint unica.

Cita questo